146 related articles for article (PubMed ID: 10362285)
1. Could bone marrow transplantation cure AIDS?: review.
Huzicka I
Med Hypotheses; 1999 Mar; 52(3):247-57. PubMed ID: 10362285
[TBL] [Abstract][Full Text] [Related]
2. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Eradication of HIV in infected patients: some potential approaches.
Yang QE
Med Sci Monit; 2004 Jul; 10(7):RA155-65. PubMed ID: 15232518
[TBL] [Abstract][Full Text] [Related]
5. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
6. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
Hossain MS; Roback JD; Lezhava L; Hillyer CD; Waller EK
Biol Blood Marrow Transplant; 2005 Mar; 11(3):169-80. PubMed ID: 15744235
[TBL] [Abstract][Full Text] [Related]
7. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
Pippi F
Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect.
Van Wijmeersch B; Sprangers B; Rutgeerts O; Lenaerts C; Landuyt W; Waer M; Billiau AD; Dubois B
Biol Blood Marrow Transplant; 2007 Jun; 13(6):627-37. PubMed ID: 17531772
[TBL] [Abstract][Full Text] [Related]
9. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
10. [Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)].
Miró JM; Antela A; Arrizabalaga J; Clotet B; Gatell JM; Guerra L; Iribarren JA; Laguna F; Moreno S; Parras F; Rubio R; Santamaría JM; Viciana P
Enferm Infecc Microbiol Clin; 2000; 18(7):329-51. PubMed ID: 11109725
[TBL] [Abstract][Full Text] [Related]
11. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus reservoir might be actively eradicated as residual malignant cells by cytotoxic chemotherapy.
Yang QE
Med Hypotheses; 2004; 62(3):358-63. PubMed ID: 14975503
[TBL] [Abstract][Full Text] [Related]
13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
14. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
15. Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia.
Lawler M; Locasciulli A; Longoni D; Schiro R; McCann SR
Bone Marrow Transplant; 2002 Mar; 29(5):453-6. PubMed ID: 11919737
[TBL] [Abstract][Full Text] [Related]
16. Effects of ex vivo activated immune cells on syngeneic and semi-allogeneic bone marrow transplantation in mice.
Yang G; Tan J; Wei G; Deng Y; Chen H; Yang D
Transpl Immunol; 2006 Nov; 16(3-4):166-71. PubMed ID: 17138049
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
18. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Har-Noy M; Slavin S
Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT).
Vindeløv L
Eur J Haematol; 2001 Feb; 66(2):73-82. PubMed ID: 11168513
[TBL] [Abstract][Full Text] [Related]
20. [Eradication of adult T-cell leukemia cells and maintenance of remission by the graft-versus-leukemia effect after allogeneic bone marrow transplantation].
Ota K; Hashino S; Shimizu K; Yonezumi M; Chiba K; Kondo T; Suzuki S; Imamura M; Asaka M
Rinsho Ketsueki; 2004 Sep; 45(9):1044-7. PubMed ID: 15510833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
